How to Gain Weight With Crohn's Disease

If you have Crohn's disease and cannot get weight back on, the single most useful thing to know is which of three problems you actually have. You may be eating less than you think, you may be absorbing less of what you eat, or your inflammation may be active enough to shift the balance. In practice most people have all three at once, but the order matters, because they have different fixes and only one of them is really about food.

The second most useful thing to know is what nobody appears to have measured. Searching PubMed and Europe PMC for this article, we could not find a single trial of weight-gain strategies in adults with Crohn's disease. No published target rate, no tested calorie prescription, no comparison of one approach against another. Every page that hands you a kilograms-per-week figure for Crohn's has borrowed it from general nutrition writing and attached your diagnosis to it. This guide goes through what the evidence does support, flags the places where the numbers do not add up, and is honest about the gaps.

The short answer: three problems wearing one name

Weight is the difference between the energy you absorb and the energy you use. Crohn's disease can push on all three terms of that equation, so "I cannot gain weight" is really three questions.

Are you eating less than you think? This is almost always part of it and it is rarely deliberate. Pain after meals, nausea, early fullness, a safe-food list that has shrunk to four items, and the quiet calculation that skipping lunch means not needing a toilet at 2pm all pull intake down without ever feeling like restriction. A study of 64 Australian children with IBD found that just over half had changed their diet after diagnosis, most often by avoiding foods, and 37.5% regularly skipped meals, with meal skipping independently associated with both food avoidance and active disease (Gammanpila 2026).

Are you absorbing less of what you eat? This is the part that makes Crohn's different from simply having a small appetite, and it is measurable. It also depends heavily on where your disease is, because the small bowel is the absorbing surface.

Is inflammation raising what you need? Yes, but by less than most articles suggest, and the effect is unreliable enough that it should not be the thing you plan around.

The reason the order matters is that only the first is something you act on directly. The second is something to get assessed. The third is what your IBD team is already treating.

Is it malabsorption, or am I just eating less?

The cleanest study on this is small and old and still the best answer anyone has. Sixteen people with Crohn's disease in remission, weight stable for more than three months and off steroids, kept three-day food records while collecting their stools. The researchers then burned the stool in a bomb calorimeter to measure how much food energy had passed straight through, measured resting energy expenditure by indirect calorimetry, and measured body composition by DXA scan (Vaisman 2006).

Split at a BMI of 18.5, the two groups had no difference in calorie intake and no difference in resting energy expenditure. What separated them was malabsorption: the lower-BMI group lost 21.1% of their food energy in stool, against 11.7% in the higher-BMI group. The authors' conclusion was blunt: resting energy expenditure does not seem to explain lower BMI, and malabsorption should be evaluated in people with Crohn's who fail to gain weight during remission.

Two caveats belong at the point of citation. The study had sixteen people in it, so about eight per group. And the abstract describes malabsorption as negatively correlated with BMI at a P value of 0.07, which is above the conventional threshold; the significant comparison is the split-group one at P = 0.015, not the correlation. Both things are true and both are worth saying out loud, because this paper gets cited as though it settled the question.

What it does establish is the practical point. If roughly a fifth of what you eat is leaving in your stool, then eating the amount a calculator tells you a person of your height needs will leave you short every day, and it will not be your fault or your willpower. That is a reason to ask your IBD team about absorption, particularly if you have had small bowel disease or an ileal resection, rather than assuming you simply need more discipline at dinner.

The "Crohn's burns more calories" claim, audited

Almost every page on this topic says inflammation raises your metabolic rate. The research behind that claim is real but much weaker and much messier than the way it is repeated.

The paper most often meant is a French study of 70 people, 41 during a flare and 29 in remission. Expressed per kilogram of fat-free mass, resting energy expenditure was 31.7 kcal/kg/day during flares against 29.4 kcal/kg/day in remission, an 8% difference that correlated with both the activity index and CRP (Rigaud 1993). Eight percent is a real effect. It is also, for most people, a couple of hundred calories.

Now compare that with an Italian study of 34 people with IBD in clinical remission and off steroids. It found basal metabolic rate per kilogram of fat-free mass was higher in Crohn's than in controls, at a median of 143 kJ/kg/day against 134 (Capristo 1998). Convert that to the units Rigaud used and the Crohn's-in-remission figure is about 34 kcal/kg/day, and the healthy control figure is about 32.

There is a further problem, which is that nobody can predict your resting needs on paper. A Greek study measured resting energy expenditure by indirect calorimetry in 186 people with Crohn's disease and compared it against fourteen predictive equations, including versions using body composition data. All fourteen underpredicted. Accuracy at the individual level ranged from 19% to 42% depending on the equation and the weight used, and stayed low when the sample was split by disease activity, sex, BMI and medication (Karachaliou 2023). Mean measured resting expenditure was 7255 kJ per day, about 1734 kcal.

Meanwhile a Brazilian study of 60 people with Crohn's compared the simple rules of thumb clinicians use, 30 and 35 kcal per kilogram, against indirect calorimetry plus 20%. It found no agreement, with the weight-based equations coming out higher than the measured values (Menezes 2025).

Those two findings look contradictory, and the resolution is that they are measuring different quantities. Karachaliou compared equations that estimate resting expenditure against measured resting expenditure. Menezes compared total-energy-expenditure targets against a measured resting value scaled up by 20%. Neither one is the other's replication. What they agree on, which is the useful part, is that a calculated number is not your number.

One more thing worth flagging in the Brazilian paper: the abstract reports a sample of 60, then gives ileocolonic involvement as 61.8% and stenosing behaviour as 45.5%. Neither percentage is achievable with a denominator of 60, and both fit a denominator of 55 almost exactly. The denominator appears to shift partway through, probably because disease phenotype was only classifiable in a subset. It does not affect the energy comparison, but it is the kind of thing worth noticing before you quote a phenotype figure.

Where the "65 to 75% are malnourished" number comes from

You will see this figure everywhere, and it deserves a closer look, because if three-quarters of people with Crohn's are malnourished then being underweight is the norm and a healthy weight is the exception. That is not what current data show.

The figure appears in a widely cited 2017 mini-review, which states that malnutrition is estimated in 65% to 75% of patients with Crohn's disease and 18% to 62% of patients with ulcerative colitis, citing four references (Scaldaferri 2017). We followed the chain. The first reference is a review of micronutrient deficiencies whose own abstract says micronutrient deficiencies occur in more than half of patients with IBD, which is a different measure of a different thing (Weisshof 2015). The third is a Brazilian body composition study of 102 outpatients that found malnutrition by BMI in 14.0% of people with Crohn's disease and 5.7% of those with ulcerative colitis (Rocha 2009). We did not read the remaining two references, so this is not a complete audit of the chain. But one of the sources offered for a 65% to 75% claim reports 14%.

Now compare the modern studies, which use standardised criteria:

So the honest range in adults attending clinics today is something like one in eight to one in three, depending entirely on which definition you use, and the higher figures come from screening tools that flag risk rather than confirmed malnutrition. The 65% to 75% number is not a lie, but it is a legacy estimate from an era of different definitions, and it is not the number to plan your expectations around.

There is one further thing worth knowing about how these numbers travel. At least one popular page on gaining weight with Crohn's renders this statistic as "nutrient malabsorption is common in Crohn's disease, affecting 65%-75% of patients" and links to the 2017 review. The review says malnutrition, not malabsorption. Those are different claims with different implications, and the substitution changes what a reader thinks is happening inside them.

The scale is the wrong instrument

Weight is what you can measure at home, so it is what everyone measures. It is also the crudest signal in this whole picture, because it cannot tell you what you gained.

The Brazilian body composition study makes the point cleanly. Malnutrition by BMI was found in 14% of people with Crohn's, but muscle mass depletion was detected in more than half of both the Crohn's and ulcerative colitis groups, and people with no BMI-based sign of malnutrition still had fat mass depletion, particularly during active disease (Rocha 2009). A normal number on the scale does not mean normal tissue underneath it.

How common is low muscle mass? It depends enormously on the definition, and the spread is worth seeing:

• In 60 IBD outpatients assessed with bioimpedance and handgrip strength, 10% met full sarcopenia criteria and 20% had myopenia, meaning low muscle mass without the strength criterion. Myopenia was strongly associated with a history of surgery, 67% against 21%, and with a lower BMI (Dermine 2025).
• In 158 IBD outpatients at an Italian centre, sarcopenia prevalence was 34.2% (Bezzio 2024).
• In 91 Polish IBD patients, myopenia by fat-free mass index reached 36.7% (Olczyk-Wieczorkowska 2026).
• In 117 Indian IBD patients assessed with CT-based muscle mass plus strength and physical performance, 40.2% had sarcopenia and a further 34.2% had probable sarcopenia (Dharap 2026).

A four-fold spread across four studies of the same condition tells you the definition is doing most of the work. It does not mean muscle loss is not real; it means "how common is sarcopenia in IBD" has no single answer yet.

Does low muscle mass actually matter, or is it just something scanners can see? The answer is genuinely mixed and the honest version is more interesting than the headline. A meta-analysis of 17 studies and 2,895 IBD patients found sarcopenia associated with treatment failure at an odds ratio of 2.00 (95% CI 1.43 to 2.79), and with needing surgery at 1.54 (1.06 to 2.23) (Feng 2024). But read further into the same abstract: in the corticosteroid cohorts the odds ratio was 1.21 (0.55 to 2.64) and in the biologic cohorts 1.65 (0.93 to 2.92), neither statistically significant, and the change-of-drug endpoint was 1.19 (0.71 to 2.01), also not significant. So the pooled result is real but it is carried by the surgery endpoint, and it is not present in either of the two drug-class subgroups the authors reported. An earlier meta-analysis of ten studies was equally careful: the raw pooled data showed no significant difference in surgery rates (OR 1.826, P = 0.089), and sarcopenia only emerged as an independent predictor once the data were adjusted (OR 2.655, P = 0.027) (Eros 2020).

If you want something more practical than a scan, handgrip strength is the measure being studied. In 144 IBD patients it showed acceptable accuracy for diagnosing malnutrition, with an area under the curve of 0.733 (0.643 to 0.824), though its correlations with disease activity were weak, at a Spearman coefficient of -0.182 (Vadarlis 2026). A coefficient that size explains around 3% of the variation, so grip strength is a nutrition signal rather than a disease-activity signal. One inconsistency: the same abstract reports a correlation of -0.218 with the number of extraintestinal manifestations at P less than 0.001, but a coefficient of that size in a sample of 144 gives a P value closer to 0.01, and the Crohn's subgroup is smaller than 144, which would make it larger still. In a Canadian cohort of 161 IBD patients followed a mean of 43.9 months, reduced grip strength was independently associated with IBD-related hospitalisation (adjusted hazard ratio 3.96, P = 0.03) while the clinical frailty scale and subjective global assessment were not, though there were only 27 hospitalisations and 13 surgeries to model (Bedard 2023).

Does treating the Crohn's put the weight back?

For many people a substantial amount comes back, faster than they expect, and then stops. Understanding that shape saves a lot of disappointment.

In a Swedish real-world study of 110 anti-TNF-naive people with Crohn's disease starting infliximab, 59% had gained weight by six weeks, with a median increase of 1.7 kg, and the proportion who had gained rose to 73% at three months and 76% at twelve. Young people, underweight people and those with fistulising disease gained the most, and the gains tracked rising albumin and falling CRP (Lepp 2020).

Then comes the subgroup check, which is where most articles stop reading. A Danish nationwide registry study of 851 people with Crohn's disease or ulcerative colitis starting infliximab found that long-term weight gain during maintenance was not observed in most patients. The striking figure, an average 7.5 kg gain, applied specifically to women with Crohn's disease who were underweight when they started. Men and women with Crohn's or colitis who began at a normal or raised BMI averaged under 2 kg during maintenance. Underweight men gained 2.9 kg (95% CI 2.1 to 3.6 for Crohn's; 1.9 to 3.9 for colitis) in the first 90 days, but neither group gained significantly during maintenance. Fewer than 3% of the whole cohort gained more than 10% of their baseline body weight, and the authors concluded that weight gain on anti-TNF therapy is unlikely to be an effect of the drug itself (Winter 2022).

Two more readings of the same question, for completeness. An Australian cohort found two-thirds of infliximab-treated IBD patients gained weight, with a mean change at twelve months of 3.3 kg and a standard deviation of 6.5 kg (Kaazan 2020). A standard deviation twice the size of the mean means that average is describing a very wide scatter, including people who lost weight, and should not be read as what will happen to you. And a post hoc analysis pooling 1,273 patients from four infliximab trials, ACCENT I, ACCENT II, ACT 1 and SONIC, found that after adjustment women gained less than men, 3.9% against 4.3% of baseline weight (P = 0.009), a difference the authors themselves described as statistically significant but not clinically relevant (Christian 2020). That is honest reporting of a result that contradicted the authors' own clinical impression, and it deserves credit. Worth naming, though: those four trials were industry-sponsored registration and comparison trials of infliximab, and we were unable to read a conflict-of-interest statement for the post hoc analysis, so we are not asserting anything about the authors' ties either way.

The practical summary is this. Getting inflammation under control is the biggest single lever on your weight, the gain is concentrated in the weeks after things improve, and it is largest if you started underweight. It is not an ongoing upward drift, and the medication is not a weight-gain drug. Our guide to telling whether you are actually in a Crohn's flare covers how to work out whether inflammation is the current problem, and interpreting the Harvey-Bradshaw Index explains the score your team is most likely tracking alongside it.

Does eating more actually work? The one study that tried

Here is the gap that should bother you: there is no modern trial of increased energy intake for weight gain in adults with Crohn's disease. The nearest thing is from 1982.

Six adolescent males with Crohn's disease and growth failure were compared with five healthy age-matched controls using nitrogen balance, whole body potassium, urinary creatinine and labelled glycine turnover. Lean body mass and muscle mass were significantly reduced in the patients. But whole body nitrogen flux, protein synthesis, breakdown and net protein retention were no different from controls, including in those with active inflammation and those on corticosteroids. The patients then received an intragastric supplement that raised protein and energy intake by 40% for seven months, and their linear and weight growth velocities became comparable to the healthy controls. The authors concluded that chronic inflammation and corticosteroid therapy were not associated with detectable changes in whole-body protein metabolism, and that dietary insufficiency appeared to be primarily responsible for the growth failure (Motil 1982).

That is six adolescent boys in one metabolic unit more than forty years ago, and it is the strongest direct evidence that eating more works in Crohn's. It is a striking indictment of how little this has been studied since. A companion paper from the same group measured mineral balance during three weeks of supplementation in the same population and found that faecal calcium, magnesium and nitrogen losses were significantly higher than in controls, that supplementation roughly doubled retention of phosphorus, nitrogen and calcium, and that phosphorus appeared to be a limiting nutrient with nutrient imbalances arising during nutritional rehabilitation (Motil 1985). In other words, catching up is not just about calories, and it is not automatically balanced.

Guidelines do not fill this gap with numbers, and they are careful not to pretend otherwise. The ESPEN guideline on clinical nutrition in IBD notes that malnutrition is highly prevalent in IBD and especially in Crohn's disease, that increased energy and protein requirements are observed in some patients, and that the management of malnutrition in IBD sits within general support for malnourished patients rather than any IBD-specific formula (Bischoff 2023). The AGA recommends that all people with IBD are screened for malnutrition and that everyone newly diagnosed has access to a registered dietitian (Hashash 2024), and the 2025 ECCO consensus likewise says every person with IBD should have access to a dietitian with IBD experience (Svolos 2025). That is the real recommendation for this question: get an individual assessment, because no one can write you a number from a web page.

Adding energy inside a small safe-food list

This is the question people actually ask, and it is the one the research is worst at answering. What follows is framed as what people commonly do and the mechanism or caveat behind it, not as a plan. Amounts, targets and combinations belong with a dietitian who knows your disease location, your surgical history and your current activity.

If your intake is limited because eating itself has become unpleasant, that is worth naming as its own problem rather than a motivation failure. Our guide to nausea after eating with Crohn's works through the mechanisms and what the timing of the nausea tells you, and if mouth pain is part of why eating has become miserable, mouth ulcers with Crohn's covers what is treatable there. During an active flare the question changes shape entirely, and what to eat during a Crohn's flare up covers texture, stricture risk and the nutrition therapies with actual trial evidence behind them, including exclusive enteral nutrition.

One guardrail that matters here: restriction is not neutral. Nothing in this section is a reason to cut foods out, and anything that would narrow your diet further should go past a dietitian first. If a low FODMAP trial has been suggested to reduce symptoms, it is a short and structured process with a planned reintroduction phase, ideally supervised, never a permanent way of eating; our post on whether low FODMAP is worth trying with Crohn's covers where that evidence actually sits.

Oral nutrition drinks, and why they so often backfire

Nutrition drinks are the standard answer to "how do I get more calories in", and the standard experience in the Crohn's community is that they cause symptoms. A thread in r/CrohnsDisease from someone who had been persistently underweight for years put it directly: they liked the drinks and could get them, but the drinks upset their stomach immediately (r/CrohnsDisease thread). The replies converged on volume and speed rather than the product. Several people described drinking a small amount every couple of hours instead of a full carton, one naming it as a technique used in hospital nutrition, and others described sipping a single drink slowly across an hour. Others mentioned peptide-based and unsweetened formulations they tolerated better, and the cost of them.

None of that is evidence. No trial has compared sipping technique, formulation or brand for tolerance or weight gain in Crohn's disease, so the community has worked this out by trial and error and is passing it on. What the guidelines do say is that oral nutritional supplements sit within general nutritional support for malnourished patients, and that individual nutrition advice is part of IBD care (Bischoff 2023). Which products are appropriate, whether they can be prescribed, and whether a period of tube feeding would be better than trying to drink your way there are all clinical questions. The same thread had someone raise exactly that with their team and get referred.

A quieter point from the same thread, and from the ones about rebuilding after a flare: people described losing teeth and needing dentures, and being told it was from malnutrition. That is not a reason to panic about a few kilograms, but it is a reason to treat persistent underweight in Crohn's as a medical issue to raise, not a cosmetic one to manage privately.

Appetite: the drugs everyone asks about, and the evidence that is not there

In every Crohn's thread about weight gain, the top replies include appetite stimulants. Cannabis, prednisone, cyproheptadine by its brand name, sometimes an antidepressant. It is worth being precise about what is known, because the answer is mostly "nothing, in this condition".

We could find no trial of any appetite stimulant in Crohn's disease for weight gain. Not cyproheptadine, not mirtazapine, not cannabis or dronabinol. Everything people cite comes from other populations.

The largest cyproheptadine trial is a multicentre randomised double-blind placebo-controlled study of 375 adults in South Korea with poor appetite, not with IBD. It reported a mean change in appetite score of -2.42 in the treatment group against -2.03 on placebo, and significant increases in weight and BMI (Kim 2021).

For mirtazapine, a 2026 systematic review of five randomised trials in cancer-associated appetite loss and cachexia found that appetite improved from baseline in most studies but only beat a control when the comparator was olanzapine, that one trial favoured the comparator, and that for weight and energy intake there was no significant difference from control in any study (Ellenberg 2026).

And prednisone, which the community treats as a certainty. In a double-blind placebo-controlled crossover trial, 55 adults with stable asthma took 10 days of prednisolone. Adherence was confirmed by a drop in eosinophils. There was no difference from placebo in serum leptin, in appetite measured on a validated visual analogue scale, in dietary intake in kJ per day, in body weight or in body fat percentage. Sleep and gastrointestinal disturbance were significantly more common on the steroid (Berthon 2015). That is a different disease and a ten-day course rather than the multi-week tapers used in IBD, and it does not disprove what people report. It does mean the near-universal certainty that steroids add weight is not resting on controlled trial data, and that when weight does go on during a course, disease control improving at the same time is a competing explanation nobody has separated out.

None of this is advice about medication. Starting, stopping or changing anything, including over-the-counter antihistamines used for appetite, is a conversation with your IBD team.

Weight or strength first? The one randomised trial in IBD

The most-asked practical question in the rebuild threads is whether to gain weight before training or train while gaining. The most upvoted answers say weight first. The evidence is thin enough that this is worth reporting precisely.

A randomised double-blind placebo-controlled trial in Shanghai gave whey protein or placebo for eight weeks to IBD patients with sarcopenia, alongside a resistance training programme three times a week. The appendicular skeletal muscle mass index rose significantly more in the protein group at four and eight weeks, and albumin rose in both groups. But there was no group-by-time interaction for BMI, five-time chair-stand time, three-metre walk speed, grip strength, waist circumference, hip circumference or waist-to-hip ratio (Zhao 2022). So the one thing that moved was the scan-derived muscle mass index; every functional measure and the scale itself were unchanged.

Two problems with that abstract are worth printing. It describes a trial of forty-five participants, then reports 15 allocated to one group and 13 to the other, which is 28, with no account of the other 17. And the headline muscle mass result is reported as "F = 1.092, P = .035". An F statistic of about 1 does not produce a P value of 0.035 at any plausible degrees of freedom; the other F statistics in the same abstract, 7.214 and 3.592, sit sensibly alongside their P values. One of those two numbers is wrong and we cannot tell which from the abstract.

So the honest position is: protein plus resistance training may help rebuild muscle in IBD, the single trial testing it is small and its reporting has errors, and it showed no change in strength or in weight. If you are underweight and have been feeling faint when you exercise, as people in the r/CrohnsDisease threads describe, that is a reason to talk to your IBD team before starting rather than to push through. Our guide to exercising with Crohn's disease covers what the broader activity evidence supports.

A worked example: twelve weeks of tracking that means something

Weight on its own is noise. Here is the shape of a record that actually answers a question, using a composite example.

Week 0. Marcus has ileal Crohn's, had a short resection four years ago and has dropped 6 kg over five months. His weight is now the lowest it has been since surgery. Rather than trying to eat more immediately, he writes down four things for his appointment: the weight trend with dates, how many days in the last fortnight he ate three times, what his stool pattern is doing compared with his usual baseline, and the list of foods he currently tolerates, which is down to seven.

Weeks 1 to 2. He logs meals, stool frequency and form, abdominal pain, and whether symptoms wake him. He does not change his diet yet, because the first job is establishing what is actually happening. The pattern that emerges: pain 40 to 90 minutes after anything with texture, meals skipped on the days he works late, and no blood.

Week 3, the appointment. He brings the log. His team sends bloods and a faecal calprotectin, and because he has had an ileal resection, asks about absorption specifically. A dietitian referral goes in. Nobody tells him to eat more yet, because if inflammation is active then intake is downstream of that.

Weeks 4 to 8. Calprotectin is raised and treatment is adjusted. His dietitian works on adding energy to the seven foods he already tolerates rather than introducing new ones, and on eating at set times because his hunger cues are unreliable. His weight does nothing for three weeks. Then it starts moving.

Weeks 9 to 12. Pain after meals has dropped, his tolerated list is up to eleven foods, and he has gained 2.4 kg. His clothes fit differently, which he notices more than the number. At the next review he and his team look at the weight trend, the activity score, whether the gain is tracking with falling inflammatory markers as it did in the infliximab cohort, and whether his grip strength has moved.

What made this work was that weight was the last thing acted on, not the first. Clairop is built for this shape of record: it calculates the Harvey-Bradshaw Index from what you log, tests each food against three delay windows rather than assuming the last meal was the culprit, and pulls the lot into a one-page report with your activity score, bowel pattern, medication adherence and labs for the appointment. The method page explains the thresholds it waits for before showing a food result, which is the difference between a pattern and a coincidence. It does not track weight, and it is not a substitute for a dietitian assessing absorption.

Micronutrients: the deficiencies weight cannot show

Gaining weight and being nourished are not the same thing, and the second is the one with clinical consequences. Micronutrient deficiencies occur in more than half of people with IBD, most commonly iron, B12, vitamin D, vitamin K, folic acid, selenium, zinc and B vitamins, more often in Crohn's than colitis, and more often in active disease (Weisshof 2015).

A US retrospective review looked specifically at the ones that get missed. Among 611 hospitalised IBD patients, of those actually tested, deficiency rates in Crohn's disease were 25.4% for copper, 53.3% for vitamin A, 23.7% for vitamin E and 29.4% for vitamin K, with associated features including anaemia, muscle weakness, fatigue, dry skin, significant weight loss and osteoporosis. The authors' point was that these are rarely checked: copper was measured in 12.3% of the cohort and vitamin K in 4.6% (Kamel 2024).

If you have lost weight, especially with small bowel disease or after a resection, which bloods to check and how often is a question for your IBD team. We are not going to suggest supplements or doses. If hair shedding has started since the weight loss, our post on Crohn's disease hair loss covers which nutritional deficiencies are genuinely implicated and which are not.

The part nobody prepares you for: getting to a healthy weight and hating it

This is the most consistent theme in the threads and the least covered part of the topic. People work for months or years to put weight back on, reach the target their doctors set, and then feel terrible about their bodies.

A widely upvoted r/CrohnsDisease thread from someone who had been as low as 115 lb at 5 feet 9, whose team set a target of 150 to 160 lb specifically so that a future flare would be less dangerous, described reaching 155 lb, being told by both GP and gastroenterologist that it was the right weight, and not being comfortable in their own skin (r/CrohnsDisease thread). The replies were full of the same story: people who had regained and felt huge, who had got rid of clothes, who had stopped taking photographs, who described sneaking food or eating alone, and several who said plainly that they had an unhealthy relationship with food. One described being formally diagnosed with anorexia after going into remission and gaining. Another described being frightened of developing an eating disorder while still underweight. A different thread captured the other side of the loop: someone six years into building their weight up, back in a four-month flare, describing being scared of losing it again (r/CrohnsDisease thread). These are individual experiences, not data, and they are not a substitute for an assessment.

The data that exists is consistent with them. In a clinic study of 161 people with IBD, 92% avoided at least one food while symptomatic and 74% kept avoiding foods even when symptom-free, and 17% screened positive for avoidant restrictive food intake disorder, a group much more likely to be at risk of malnutrition (Yelencich 2022). A qualitative meta-synthesis of 19 studies described food avoidance in IBD producing social alienation, alienation from food culture and disrupted life planning, alongside the practical difficulty of "safe recipes updated in failure" (Wang 2025). A Chinese study of 323 IBD patients sorted them into three food-avoidance profiles, with 27.2% in the most severe group, where higher fear of disease progression and more negative illness perception were the associated factors and being in remission predicted the milder profiles (Wang 2026).

One honest caveat about that last study: the three groups avoided on average 2.78, 3.59 and 3.89 foods respectively, so the difference between the "mild" and "severe" labels is about one food. The labels come from a latent profile analysis across several measures including food pleasure and impairment, not from a count of avoided foods, but the numbers do not support reading "severe food avoidance" as a very long list. A specialist commentary in this area made the case directly that food avoidance in IBD is itself something to prevent and treat, not just a symptom to record (Godny 2023).

Our guide to whether restricted eating can tip into a disorder goes through the warning signs in more depth, and the counterpart question, whether you can be overweight with Crohn's disease, covers the other direction of this same disbelief, including what happens to your care when your weight is not the signal your team is watching.

Myths worth retiring

"You cannot gain weight with Crohn's because it burns too many calories." The metabolic effect is real but small, and it did not separate underweight from normal-weight people with Crohn's in remission in the one study that measured intake, expenditure and stool losses together (Vaisman 2006). Between-study variation in resting expenditure per kilogram of lean tissue is larger than the flare-versus-remission difference (Rigaud 1993, Capristo 1998).

"65 to 75% of people with Crohn's are malnourished." That estimate predates standardised criteria. Current studies find roughly 12% to 23% depending on the definition used (Korwel 2026, Bezzio 2024, Vigano 2024), and one of the sources offered for the older figure reports 14% (Rocha 2009).

"A normal BMI means my nutrition is fine." More than half of both Crohn's and colitis patients in one body composition study had muscle mass depletion, including people with no BMI-based sign of malnutrition (Rocha 2009). Low muscle mass turns up in 20% to 40% of IBD cohorts depending on definition (Dermine 2025, Dharap 2026).

"Biologics make you gain weight." A national study of 851 patients found no general long-term weight gain on infliximab, with the substantial gains confined to underweight patients and under 3% of the whole cohort gaining more than 10% of baseline weight (Winter 2022). What changes is the disease, not the metabolism.

"A calorie calculator will tell me my target." All fourteen predictive equations tested against indirect calorimetry in 186 people with Crohn's underestimated resting expenditure, with individual-level accuracy under half (Karachaliou 2023).

"There is a proven amount I should be eating to gain weight." There is not, for adults with Crohn's. The nearest direct evidence is a 40% increase in protein and energy in six adolescent boys in 1982 (Motil 1982). Guidelines respond to that gap by recommending individual dietitian assessment, not a number (Bischoff 2023, Hashash 2024).

"Eating less is the safe option while I work out my triggers." Restriction has its own cost. Three-quarters of IBD patients in one study kept avoiding foods when symptom-free, and 17% screened positive for a restrictive eating disorder (Yelencich 2022).

When to see a doctor promptly

Unexplained or continuing weight loss is a medical symptom, not a nutrition project. Contact your IBD team or GP promptly if you have:

• Weight that is still falling despite eating as much as you can manage
• New blood in your stool, or more than usual
• Symptoms that wake you at night
• New or worsening abdominal pain, particularly if it comes with vomiting or a swollen abdomen
• A fever, or feeling generally unwell alongside the weight loss
• Unusual tiredness or breathlessness, which can be a sign of anaemia
• Difficulty eating because of mouth pain, nausea, or pain on swallowing
• Any change in bowel pattern that has persisted beyond a few days and is not tracking with food

Seek urgent same-day medical help if you cannot keep fluids down, have severe abdominal pain with a tender or distended abdomen, have stopped passing stool or wind with pain and vomiting, or have signs of dehydration such as dizziness on standing or passing very little urine. Obstruction is a particular risk if you have stricturing Crohn's disease, and it is not something to manage at home with softer food.

Ask specifically for a dietitian referral if weight is your problem. Both the AGA and ECCO say everyone with IBD should have access to one (Hashash 2024, Svolos 2025), and absorption assessment is not something you can do yourself.

The honest bottom line

Gaining weight with Crohn's disease is mostly not a diet problem. It is an inflammation problem, then an absorption problem, then an intake problem, and the order those get addressed in determines whether anything works. Controlling the disease is the biggest lever, and when it works the gain arrives in the first weeks rather than accumulating for years. Absorption is worth measuring rather than assuming, especially with small bowel disease or a resection. And intake is the piece you can work on, ideally with a dietitian, by adding energy to what you already tolerate rather than by expanding a safe-food list while your gut is unhappy.

What you will not find anywhere, including here, is a number. We could find no trial testing how fast adults with Crohn's should gain, what intake target to aim for, which nutrition drink is best tolerated, whether meal frequency matters, or whether any appetite stimulant works in this condition. That absence is the most important thing on this page, because it means the confident numbers elsewhere were not measured in anyone like you. For more on tracking, activity scores and getting the most out of appointments, browse our Crohn's disease guides.